Van der Niepen P, Sennesael J J, Verbeelen D L
University Hospital, Free University of Brussels, Belgium.
Nephrol Dial Transplant. 1995;10(9):1689-95.
The effect of different dialysis modes on kinin kinetics was studied in seven stable haemodialysis patients treated with AN69 dialysers and ACE inhibitors (ACEI). AN69 haemodiafiltration with calcium-enriched substitution (HDF), AN69 haemodialysis with 1.75 (HD 1.75) and 1.50 (HD 1.50) mmol/l dialysate calcium, AN69 haemodialysis with 1.25 mmol/l dialysate calcium and substitution of 2.25 mmol/h calcium (HD+Ca), and cellulose acetate haemodiafiltration (CA HDF) were compared. Dialysis was uneventful in all patients. During dialysis, serum calcium, sodium, pH, albumin, and bradykinin were measured at the start and after 5 min at arterial, venous, and postinfusion side of the extracorporeal circuit. Serum predialysis bradykinin was 107 +/- 18fmol/ml (mean +/- SEM) in patients on HDF, 61 +/- 9 fmol/ml in patients on HD 1.50, 49 +/- 13 fmol/ml in patients on HD 1.75, 35 +/- 3 fmol/l in patients on HD+Ca, and 75 +/- 27 fmol/ml in CA HDF. No significant change of mean bradykinin levels occurred after 5 min at the arterial and venous side of the dialyser or postinfusion. Individual high bradykinin levels, up to 2672 fmol/ml, were observed but without clinical consequences, suggesting that the threshold value is difficult to determine. No significant correlations were evidenced between bradykinin levels and any of the biochemical measurements. The present data show an intraindividual variability of the bradykinin levels with variation coefficients ranging from 0.386 to 2.783. The present study illustrates that haemodialysis and haemodiafiltration with AN69 in ACEI-treated patients, under the present conditions, does not result in anaphylactoid reactions or in a clinically significant release of bradykinin.(ABSTRACT TRUNCATED AT 250 WORDS)
在7例接受AN69透析器和血管紧张素转换酶抑制剂(ACEI)治疗的稳定血液透析患者中,研究了不同透析模式对激肽动力学的影响。比较了采用富钙置换的AN69血液透析滤过(HDF)、透析液钙浓度为1.75(HD 1.75)和1.50(HD 1.50)mmol/l的AN69血液透析、透析液钙浓度为1.25 mmol/l且钙置换量为2.25 mmol/h的AN69血液透析(HD+Ca)以及醋酸纤维素血液透析滤过(CA HDF)。所有患者透析过程均顺利。透析期间,在体外循环的动脉端、静脉端和输液后端开始时及5分钟后测量血清钙、钠、pH、白蛋白和缓激肽。接受HDF治疗的患者透析前血清缓激肽为107±18fmol/ml(均值±标准误),HD 1.50治疗的患者为61±9 fmol/ml,HD 1.75治疗的患者为49±13 fmol/ml,HD+Ca治疗的患者为35±3 fmol/l,CA HDF治疗的患者为75±27 fmol/ml。在透析器动脉端和静脉端或输液后5分钟后,平均缓激肽水平无显著变化。观察到个体缓激肽水平高达2672 fmol/ml,但无临床后果,提示阈值难以确定。缓激肽水平与任何生化指标之间均无显著相关性。目前的数据显示缓激肽水平存在个体内变异性,变异系数范围为0.386至2.783。本研究表明,在目前条件下,ACEI治疗患者使用AN69进行血液透析和血液透析滤过不会导致类过敏反应或临床上显著的缓激肽释放。(摘要截短至250字)